ArticleGlobal heart2026
Quality of Life Assessment in Heart Failure Patients: Insights from a Low- to Middle-Income Country.
Article in Global heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) continues to have an immense impact, not only on tangible outcomes such as mortality, but also on patients' health-related quality of life (QoL). The aim of this study was to assess the QoL of patients living with HF using the Kansas City Cardiomyopathy Questionnaire (KCCQ-12). Methods: The study considered consecutive patients of either gender, between 18 and 80 years of age, who had been diagnosed with HF with reduced ejection fraction for at least six months and who presented to the outpatient department for routine clinical follow-up. The QoL was assessed using KCCQ-12. Results: A total of 320 patients were included in this analysis; 257 (80.3%) were male, and the mean age was 54.9 ± 12.7 years, with 25 (7.8%) patients >70 years. The median time since HF was 24 (12-60) months. The median overall QoL score was 50.5 (32-75), with 81 (25.3%) categorized as good, 83 (25.9%) as moderate, 99 (30.9%) as poor, and 57 (17.8%) as having very poor QoL. In multivariable analysis, age >70 years, presence of diabetes, and non-adherence to medication were found to be independently associated with poor QoL, with adjusted odds ratios of 2.93 [1.06-8.06], 2.76 [1.66-4.61], and 1.72 [1.07-2.77], respectively. Conclusion: We observed good QoL in only one-fourth of the patients living with HF. Further, we observed that older age (>70 years), presence of diabetes, and non-adherence to medication were significantly associated with poorer QoL. These results underscore the need for targeted interventions to improve medication adherence and manage comorbidities, particularly diabetes, in order to enhance the QoL of HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.